{"component": "clause", "props": {"groups": [{"snippet_links": [{"key": "no-loan-party", "type": "definition", "offset": [0, 13]}, {"key": "company-will", "type": "clause", "offset": [42, 54]}, {"key": "restricted-subsidiaries", "type": "clause", "offset": [81, 104]}, {"key": "limited-liability-companies", "type": "clause", "offset": [114, 141]}, {"key": "to-amend", "type": "definition", "offset": [142, 150]}, {"key": "agreement-to", "type": "definition", "offset": [165, 177]}, {"key": "article-8-of-the-uniform-commercial-code", "type": "clause", "offset": [190, 230]}, {"key": "membership-interests", "type": "clause", "offset": [244, 264]}, {"key": "meaning-of", "type": "definition", "offset": [301, 311]}, {"key": "section-8", "type": "definition", "offset": [312, 321]}], "snippet": "No Loan Party that is a limited liability company will or will permit any of its Restricted Subsidiaries that are limited liability companies to amend its operating agreement to \u201copt in\u201d to Article 8 of the Uniform Commercial Code and have its membership interests be treated as securities within the meaning of Section 8-102 of the Uniform Commercial Code.", "samples": [{"hash": "jKJkYrLFDvw", "uri": "/contracts/jKJkYrLFDvw#opt-in", "label": "Forbearance Agreement and Fourth Amendment to Loan and Security Agreement (TENOR CAPITAL MANAGEMENT Co., L.P.)", "score": 35.8282012939, "published": true}, {"hash": "g1DRiQtpOlx", "uri": "/contracts/g1DRiQtpOlx#opt-in", "label": "Forbearance Agreement and Fourth Amendment to Loan and Security Agreement (Endurant Capital Management LP)", "score": 35.8282012939, "published": true}, {"hash": "cet6MRR1Ejb", "uri": "/contracts/cet6MRR1Ejb#opt-in", "label": "Forbearance Agreement and Fourth Amendment to Loan and Security Agreement (DG Capital Management, LLC)", "score": 35.8282012939, "published": true}], "size": 4, "hash": "8be326dfbccee4419140babb7060dc20", "id": 7}, {"snippet_links": [{"key": "in-the-agreement", "type": "clause", "offset": [12, 28]}, {"key": "the-parties", "type": "clause", "offset": [30, 41]}, {"key": "to-receive", "type": "definition", "offset": [117, 127]}, {"key": "information-from", "type": "clause", "offset": [148, 164]}, {"key": "will-provide", "type": "clause", "offset": [267, 279]}, {"key": "information-of", "type": "clause", "offset": [305, 319]}, {"key": "company-agrees", "type": "clause", "offset": [348, 362]}, {"key": "for-purposes", "type": "definition", "offset": [414, 426]}], "snippet": "If outlined in the Agreement, the Parties may offer Entrants a chance to \u201copt-in\u201d, by actively giving their consent, to receive specific additional information from Corus or Company or both, as further described in Section 6(c) of the Agreement (the \u201cOpt-In\u201d). Corus will provide Company with the Entrant Information of those who Opt-In as long as Company agrees that it will use the Entrant Information: (i) only for purposes outlined in the Agreement;", "samples": [{"hash": "8FAE6UK3C7o", "uri": "/contracts/8FAE6UK3C7o#opt-in", "label": "Contest Prizing Agreement", "score": 31.3592147827, "published": true}, {"hash": "5tNt7tjCVLA", "uri": "/contracts/5tNt7tjCVLA#opt-in", "label": "Contest Prizing Agreement", "score": 31.3099422455, "published": true}, {"hash": "k5b1l0I5RZ2", "uri": "/contracts/k5b1l0I5RZ2#opt-in", "label": "Contest Prizing Agreement", "score": 31.252456665, "published": true}], "size": 5, "hash": "835306149c873a5aa4b76d45228024f3", "id": 4}, {"snippet_links": [{"key": "the-credit-union", "type": "definition", "offset": [25, 41]}, {"key": "pay-point", "type": "definition", "offset": [45, 54]}, {"key": "debit-card-transactions", "type": "definition", "offset": [63, 86]}, {"key": "atm-transactions", "type": "definition", "offset": [90, 106]}, {"key": "your-account-balance", "type": "clause", "offset": [125, 145]}, {"key": "sufficient-funds", "type": "clause", "offset": [221, 237]}, {"key": "types-of-transactions", "type": "definition", "offset": [253, 274]}, {"key": "the-transactions", "type": "clause", "offset": [332, 348]}, {"key": "notify-us", "type": "clause", "offset": [359, 368]}, {"key": "in-writing", "type": "definition", "offset": [369, 379]}, {"key": "you-choose", "type": "definition", "offset": [383, 393]}], "snippet": "If you wish to authorize the Credit Union to pay point-of-sale debit card transactions or ATM transactions which will exceed your account balance taking your account into the negative, you must opt-in. If you do not have sufficient funds to cover these types of transactions, and choose not to opt-in, the Credit Union will decline the transactions. You must notify us in writing if you choose to opt-in to these transactions. Also, you must notify us in writing if, at a later date, you choose to opt-out of these transactions.", "samples": [{"hash": "hi4muInPofO", "uri": "/contracts/hi4muInPofO#opt-in", "label": "Membership Agreement", "score": 22.6317596436, "published": true}, {"hash": "7a1lZ4OR5PZ", "uri": "/contracts/7a1lZ4OR5PZ#opt-in", "label": "Membership Agreement", "score": 22.6317596436, "published": true}, {"hash": "5HYZR9Eru5k", "uri": "/contracts/5HYZR9Eru5k#opt-in", "label": "Membership Agreement", "score": 22.6317596436, "published": true}], "size": 5, "hash": "da92ec68f8cdbb0e741c7b8a2483c7d7", "id": 5}, {"snippet_links": [{"key": "the-interest", "type": "definition", "offset": [0, 12]}, {"key": "defined-in-section", "type": "clause", "offset": [49, 67]}, {"key": "article-8-of-the-ucc", "type": "clause", "offset": [202, 222]}, {"key": "meaning-of", "type": "definition", "offset": [235, 245]}, {"key": "for-the-purposes-of", "type": "clause", "offset": [285, 304]}, {"key": "the-provisions-of-article", "type": "clause", "offset": [347, 372]}], "snippet": "The Interest shall be considered a \u201csecurity\u201d as defined in Section 104.8102(1)(o) of the UCC, and this statement shall constitute an express provision that each such Interest is a security governed by Article 8 of the UCC, within the meaning of Section 104.8103(3) of the UCC, solely for the purposes of establishing the applicability thereto of the provisions of Article 8 governing", "samples": [{"hash": "lTjIgOHPVMs", "uri": "/contracts/lTjIgOHPVMs#opt-in", "label": "Limited Liability Company Agreement (DT Management LLC)", "score": 28.2375087738, "published": true}, {"hash": "ayg46gTQVCQ", "uri": "/contracts/ayg46gTQVCQ#opt-in", "label": "Limited Liability Company Agreement (DT Management LLC)", "score": 28.2375087738, "published": true}, {"hash": "9aNInD0APDE", "uri": "/contracts/9aNInD0APDE#opt-in", "label": "Limited Liability Company Agreement (DT Management LLC)", "score": 28.2375087738, "published": true}], "size": 12, "hash": "183191e24bba1c1738a11fec62385526", "id": 1}, {"snippet_links": [{"key": "a-party", "type": "clause", "offset": [3, 10]}, {"key": "additional-indication", "type": "definition", "offset": [20, 41]}, {"key": "such-party", "type": "clause", "offset": [56, 66]}, {"key": "right-to-exercise", "type": "clause", "offset": [93, 110]}, {"key": "notice-to-the", "type": "clause", "offset": [180, 193]}, {"key": "other-party", "type": "clause", "offset": [194, 205]}, {"key": "provided-however", "type": "clause", "offset": [289, 305]}, {"key": "exercise-of", "type": "clause", "offset": [314, 325]}, {"key": "date-of", "type": "clause", "offset": [389, 396]}, {"key": "for-clarity", "type": "clause", "offset": [402, 413]}, {"key": "with-respect-to", "type": "clause", "offset": [554, 569]}, {"key": "effective-as-of-the", "type": "clause", "offset": [618, 637]}, {"key": "funding-party", "type": "definition", "offset": [703, 716]}, {"key": "in-payment", "type": "clause", "offset": [737, 747]}, {"key": "equal-to", "type": "definition", "offset": [750, 758]}, {"key": "sum-of", "type": "clause", "offset": [763, 769]}, {"key": "the-case", "type": "definition", "offset": [790, 798]}, {"key": "development-expenses", "type": "definition", "offset": [910, 930]}, {"key": "the-party", "type": "clause", "offset": [1012, 1021]}, {"key": "funding-deficiency", "type": "clause", "offset": [1087, 1105]}, {"key": "due-and-payable", "type": "definition", "offset": [1199, 1214]}, {"key": "notice-of", "type": "definition", "offset": [1255, 1264]}, {"key": "payment-to-the", "type": "clause", "offset": [1339, 1353]}, {"key": "contribution-allocation", "type": "clause", "offset": [1382, 1405]}, {"key": "day-of", "type": "clause", "offset": [1440, 1446]}, {"key": "calendar-quarter", "type": "definition", "offset": [1451, 1467]}, {"key": "payment-of-the-funding", "type": "clause", "offset": [1514, 1536]}, {"key": "appropriate-notice", "type": "definition", "offset": [1635, 1653]}, {"key": "contemplated-hereby", "type": "clause", "offset": [1657, 1676]}, {"key": "from-and-after-the-effective-date", "type": "clause", "offset": [1729, 1762]}, {"key": "the-provisions-of-section", "type": "clause", "offset": [1779, 1804]}, {"key": "no-further-force-or-effect", "type": "clause", "offset": [1824, 1850]}], "snippet": "If a Party makes an Additional Indication Opt-Out, then such Party shall thereafter have the right to exercise an Opt-In for such Additional Indication, exercisable [*] by written notice to the other Party during the [*] period following [*], but in any event no later than [*] after [*]; provided however that no exercise of an Opt-In for such Additional Indication may be made after the date of [*]. For clarity, a Party shall have the right to exercise its Opt-In right following [*]. Such notice shall specify that such Party is exercising an Opt-In with respect to such Additional Indication. The Opt-In shall be effective as of the date (after such notice) on which such Party pays in full to the Funding Party an amount (the \u201cOpt-In Payment\u201d) equal to the sum of: (i) [*] or [*], as the case may be (depending on whether such Party had reduced its funding to [*] or to [*]) of all Additional Indication Development Expenses that the Funding Party incurred through the date of such payment and as to which the Party exercising such Opt-In had not previously paid [*] thereof (the \u201cFunding Deficiency\u201d), plus (ii) a premium equal to [*] of such Funding Deficiency. Such Opt-In Payment shall be due and payable no later than [*] following delivery of notice of such Opt-In[*]. For clarity, (x) upon such Party\u2019s payment of such Opt-In Payment to the Funding Party, such Party\u2019s Contribution Allocation shall be adjusted, as of the last day of the Calendar Quarter in which such payment is made, to reflect its payment of the Funding Deficiency, and (y) no Opt-In shall be effective until the Party exercising such Opt-In has given appropriate notice as contemplated hereby and has paid the full amount of the Opt-In Payment. From and after the effective date of such Opt-In, the provisions of Section 8.5(b) shall be of no further force or effect with respect to such Additional Indication[*].", "samples": [{"hash": "8XxQElTBgLG", "uri": "/contracts/8XxQElTBgLG#opt-in", "label": "License and Collaboration Agreement (Ovid Therapeutics Inc.)", "score": 28.2717323303, "published": true}, {"hash": "7QX0wINzbpz", "uri": "/contracts/7QX0wINzbpz#opt-in", "label": "License and Collaboration Agreement (Ovid Therapeutics Inc.)", "score": 28.2142372131, "published": true}], "size": 5, "hash": "e3c17ca8f4988576de704084303dace2", "id": 6}, {"snippet_links": [{"key": "the-membership-interests", "type": "clause", "offset": [0, 24]}, {"key": "article-8", "type": "definition", "offset": [46, 55]}, {"key": "uniform-commercial-code", "type": "definition", "offset": [72, 95]}, {"key": "for-purposes", "type": "definition", "offset": [131, 143]}], "snippet": "The Membership Interests shall be governed by Article 8 of the Delaware Uniform Commercial Code and shall be considered securities for purposes thereof.", "samples": [{"hash": "j9RcUqixI1l", "uri": "/contracts/j9RcUqixI1l#opt-in", "label": "Limited Liability Company Agreement (Verity Administrators, Inc.)", "score": 26.2621498108, "published": true}, {"hash": "hgNT2ulU99O", "uri": "/contracts/hgNT2ulU99O#opt-in", "label": "Limited Liability Company Agreement (Verity Administrators, Inc.)", "score": 26.2621498108, "published": true}, {"hash": "hMo9O88xZ0H", "uri": "/contracts/hMo9O88xZ0H#opt-in", "label": "Limited Liability Company Agreement (Verity Administrators, Inc.)", "score": 26.2621498108, "published": true}], "size": 10, "hash": "63da525bb0046f0f87d80c68e20ad938", "id": 2}, {"snippet_links": [{"key": "meaning-of", "type": "definition", "offset": [51, 61]}, {"key": "article-8-of-the-uniform-commercial-code", "type": "clause", "offset": [84, 124]}, {"key": "section-8", "type": "definition", "offset": [136, 145]}, {"key": "in-effect", "type": "clause", "offset": [169, 178]}, {"key": "from-time-to-time", "type": "clause", "offset": [179, 196]}, {"key": "state-of-delaware", "type": "definition", "offset": [204, 221]}, {"key": "provisions-of-the", "type": "clause", "offset": [250, 267]}, {"key": "applicable-jurisdiction", "type": "definition", "offset": [305, 328]}, {"key": "national-conference", "type": "definition", "offset": [463, 482]}, {"key": "state-laws", "type": "definition", "offset": [511, 521]}, {"key": "approved-by", "type": "definition", "offset": [526, 537]}, {"key": "bar-association", "type": "definition", "offset": [551, 566]}, {"key": "on-february", "type": "clause", "offset": [567, 578]}], "snippet": "Each Unit shall constitute a \u201csecurity\u201d within the meaning of, and governed by, (i) Article 8 of the Uniform Commercial Code (including Section 8-102(a)(15) thereof) as in effect from time to time in the State of Delaware, and (ii) the corresponding provisions of the Uniform Commercial Code of any other applicable jurisdiction that now or hereafter substantially includes the 1994 revisions to Article 8 thereof as adopted by the American Law Institute and the National Conference of Commissioners on Uniform State Laws and approved by the American Bar Association on February 14, 1995.", "samples": [{"hash": "iGAG7W1FsyF", "uri": "/contracts/iGAG7W1FsyF#opt-in", "label": "Limited Liability Company Agreement (HIC San Pablo Limited, Inc.)", "score": 26.4743328094, "published": true}, {"hash": "hF7qedxmBcD", "uri": "/contracts/hF7qedxmBcD#opt-in", "label": "Limited Liability Company Agreement (HIC San Pablo Limited, Inc.)", "score": 26.4743328094, "published": true}, {"hash": "ghGvuhk0VaQ", "uri": "/contracts/ghGvuhk0VaQ#opt-in", "label": "Limited Liability Company Agreement (HIC San Pablo Limited, Inc.)", "score": 26.4743328094, "published": true}], "size": 8, "hash": "38ab8e737e8bd93d68283918355373ee", "id": 3}, {"snippet_links": [{"key": "database-lock", "type": "definition", "offset": [50, 63]}, {"key": "exclusive-product", "type": "definition", "offset": [91, 108]}, {"key": "all-material-information", "type": "clause", "offset": [147, 171]}, {"key": "in-making-an", "type": "clause", "offset": [192, 204]}, {"key": "section-31", "type": "definition", "offset": [250, 261]}, {"key": "written-report", "type": "definition", "offset": [720, 734]}, {"key": "form-and-content", "type": "clause", "offset": [791, 807]}, {"key": "prepared-for", "type": "definition", "offset": [880, 892]}, {"key": "internal-use", "type": "definition", "offset": [897, 909]}, {"key": "relating-to", "type": "definition", "offset": [930, 941]}, {"key": "copies-of", "type": "definition", "offset": [1068, 1077]}, {"key": "preliminary-decision", "type": "definition", "offset": [1168, 1188]}, {"key": "in-notice", "type": "clause", "offset": [1241, 1250]}, {"key": "in-accordance-with", "type": "clause", "offset": [1321, 1339]}, {"key": "further-information", "type": "definition", "offset": [1377, 1396]}, {"key": "in-no-event", "type": "clause", "offset": [1505, 1516]}, {"key": "provision-of-a", "type": "clause", "offset": [1550, 1564]}, {"key": "days-after", "type": "definition", "offset": [1592, 1602]}, {"key": "provide-a", "type": "definition", "offset": [1649, 1658]}, {"key": "notice-by-the", "type": "clause", "offset": [1678, 1691]}, {"key": "extended-deadline", "type": "definition", "offset": [1706, 1723]}, {"key": "such-information", "type": "definition", "offset": [1818, 1834]}, {"key": "development-of", "type": "clause", "offset": [1887, 1901]}, {"key": "pursuant-to-section", "type": "definition", "offset": [1973, 1992]}, {"key": "the-parties-shall", "type": "clause", "offset": [2469, 2486]}, {"key": "joint-development-plan", "type": "definition", "offset": [2574, 2596]}, {"key": "joint-budget", "type": "definition", "offset": [2609, 2621]}, {"key": "parts-of-this-agreement", "type": "clause", "offset": [2630, 2653]}, {"key": "pertaining-to", "type": "definition", "offset": [2654, 2667]}, {"key": "collaboration-products", "type": "definition", "offset": [2668, 2690]}, {"key": "provided-that", "type": "clause", "offset": [2729, 2742]}, {"key": "in-the-event", "type": "clause", "offset": [2826, 2838]}, {"key": "the-relevant", "type": "clause", "offset": [3274, 3286]}, {"key": "simultaneously-with", "type": "clause", "offset": [3336, 3355]}, {"key": "submission-of-the", "type": "clause", "offset": [3362, 3379]}, {"key": "relates-to", "type": "definition", "offset": [3452, 3462]}, {"key": "to-the-extent", "type": "clause", "offset": [3516, 3529]}, {"key": "a-copy-of", "type": "clause", "offset": [3558, 3567]}, {"key": "without-limitation", "type": "clause", "offset": [3702, 3720]}, {"key": "scope-of", "type": "definition", "offset": [3756, 3764]}, {"key": "make-available", "type": "definition", "offset": [3814, 3828]}, {"key": "answer-questions", "type": "clause", "offset": [3847, 3863]}, {"key": "matters-disclosed", "type": "definition", "offset": [3887, 3904]}, {"key": "after-receipt-of", "type": "clause", "offset": [4003, 4019]}, {"key": "in-period", "type": "clause", "offset": [4040, 4049]}, {"key": "determine-whether", "type": "clause", "offset": [4055, 4072]}, {"key": "development-and-commercialization", "type": "clause", "offset": [4134, 4167]}, {"key": "notice-to", "type": "definition", "offset": [4310, 4319]}, {"key": "prior-to-the", "type": "clause", "offset": [4350, 4362]}, {"key": "expiration-of-the", "type": "clause", "offset": [4363, 4380]}, {"key": "effective-as-of-the", "type": "clause", "offset": [4445, 4464]}, {"key": "date-of", "type": "clause", "offset": [4465, 4472]}, {"key": "product-set", "type": "clause", "offset": [4613, 4624]}, {"key": "exclusive-license", "type": "definition", "offset": [4694, 4711]}, {"key": "the-collaboration", "type": "clause", "offset": [4728, 4745]}, {"key": "the-terms", "type": "clause", "offset": [4757, 4766]}, {"key": "the-parties-will", "type": "clause", "offset": [4936, 4952]}, {"key": "joint-development-costs", "type": "definition", "offset": [4963, 4986]}, {"key": "expenses-and", "type": "clause", "offset": [5006, 5018]}, {"key": "collaboration-product-profit", "type": "definition", "offset": [5019, 5047]}, {"key": "terms-of-this-agreement", "type": "clause", "offset": [5106, 5129]}, {"key": "and-oversight", "type": "clause", "offset": [5130, 5143]}, {"key": "with-respect-to-an", "type": "clause", "offset": [5208, 5226]}, {"key": "to-pay", "type": "clause", "offset": [5480, 5486]}, {"key": "article-10", "type": "definition", "offset": [5533, 5543]}, {"key": "confidential-information-of", "type": "clause", "offset": [5622, 5649]}, {"key": "for-the-purpose-of", "type": "definition", "offset": [5691, 5709]}, {"key": "all-information-disclosed", "type": "clause", "offset": [5745, 5770]}], "snippet": "3.1.1 As soon as reasonably practicable after the database lock of the first [***] of each Exclusive Product, Genmab will begin providing SGI with all material information necessary or useful in making an Opt-In Decision as further specified in this Section 3.1\n3.1.2 [***] shall invite [***] to [***] meeting to be held within [***]. At this meeting [***] will present (a) all relevant [***] to be included in the [***], (b) a package summarizing the [***] conducted on such Exclusive Product (including providing [***] with [***] to the [***]), (c) a [***] and related [***] for such Exclusive Product (assuming for the purpose that it is a [***]) and a [***] for [***] in the [***] and [***] (i.e., the [***]), (d) a written report on the [***] for such [***], including the [***] with a form and content as decided by [***], but no less detailed than the [***] that [***] has prepared for its internal use and (e) information relating to [***] within the [***] of [***] and [***] to [***], any [***] listing [***] within the [***] of [***] and [***] to [***], and copies of [***] to and from the [***] for the [***]. SGI shall provide [***] with [***] stating its preliminary decision as to whether it wishes to opt-in (\u201cPreliminary Opt-In Notice\u201d) within [***] days [***] the [***], as such deadline may be extended in accordance with this Section 3.1.2. SGI may identify further information it [***] is [***] to be provided by Genmab. The [***] shall [***] this [***] until [***] is [***], however, in no event should this [***] (including the provision of a [***]) extend beyond [***] days after the [***] of the [***].\n3.1.3 If SGI does not provide a Preliminary Opt-In Notice by the deadline (the extended deadline in Section 3.1.2 shall apply if [***] has identified further information and not yet received such information), Genmab shall then be entitled to proceed with the development of such Exclusive Product, however, SGI shall still be entitled to opt-in pursuant to Section 3.1.5. If SGI subsequently provides an Opt-In Notice with respect to such Exclusive Product within the timeframe set forth in Section 3.1.5, then the [***] to [***] the [***] incurred by [***] in the [***] after the [***] of the [***] and until the [***] as if they had been [***]. If SGI provides a Preliminary Opt-In Notice by the deadline (the extended deadline in Section 3.1.2 shall apply if SGI has identified further information and not yet received such information), the Parties shall then proceed with the Development of such Collaboration Product in accordance with the Joint Development Plan and related Joint Budget and all parts of this Agreement pertaining to Collaboration Products shall apply subject to a final [***]; provided that [***] shall not be [***] to [***] for its [***] of the [***] incurred in the [***] in the event that subsequently it does not provide an [***]. If [***] after having provided a [***] does not provide an [***] with respect to such [***] within the [***] set forth in Section 3.1.5, the [***] acknowledge that such a [***] shall not be deemed an [***], but that the [***] in question shall go back to being [***] an [***].\n3.1.4 Genmab shall provide SGI with the [***], including the [***], [***], [***], [***] and [***] of [***] of the relevant Exclusive Product within [***] days after [***]. Simultaneously with [***] submission of the [***], [***] shall notify SGI of any [***] or [***] with any [***] that relates to the Exclusive Product (other than a [***]) and shall to the extent possible provide [***] with a copy of any such agreement, provided, that, [***] may [***] from such agreement(s) any terms that are [***], so long as the [***], including, without limitation, [***] relating to [***] by [***], scope of [***] and [***] terms, remain [***]. [***] shall make available suitably [***] to answer questions relating to any of the matters disclosed pursuant to this Section 3.1 prior to and during the [***].\n3.1.5 SGI shall have until [***] days after receipt of the [***] (the \u201cOpt-In Period\u201d) to determine whether SGI will elect to opt-in (the \u201cOpt-In Right\u201d) to co-fund the development and commercialization of the Exclusive Product (the \u201cOpt-In Decision\u201d).\n3.1.6 If SGI exercises its Opt-In Right for an Exclusive Product, SGI shall provide written notice to Genmab of its Opt-In Decision prior to the expiration of the Opt-In Period for such Exclusive Product (the \u201cOpt-In Notice\u201d). Effective as of the date of such Opt-In Notice, (a) the Exclusive Product will be deemed to be a Collaboration Product, (b) Genmab\u2019s license for the relevant Exclusive Product set forth in Section 2.1.1 will terminate and SGI will grant Genmab a co-exclusive license with respect to the Collaboration Product on the terms set forth in Section 2.1.2, (c) Genmab will grant SGI a co-exclusive license with respect to such Collaboration Product on the terms set forth in Section 2.4.2, and (d) the Parties will [***] all Joint Development Costs, Commercialization Expenses and Collaboration Product Profit for such Collaboration Product, subject to the applicable terms of this Agreement and oversight of the JSC.\n3.1.7 If [***] does not provide [***] with an [***] with respect to an Exclusive Product during the relevant [***], then [***] shall have [***] to [***] with respect to such Exclusive Product and [***] shall [***] the [***] to [***] such Exclusive Product on its own granted pursuant to Section 2.1.1 and shall be obligated to pay [***] the [***], [***] and [***] set forth in Article 10.\n3.1.8 [***] agrees that the [***] disclosed pursuant to Section 3.1 shall be Confidential Information of [***] and to use such information solely for the purpose of making the [***]. SGI shall return all information disclosed pursuant to Section 3.1 to Genmab (and shall not keep any copies of such information) not later than [***] days after the [***] of the [***] unless [***] exercised its [***].", "samples": [{"hash": "klsoJvkwYek", "uri": "/contracts/klsoJvkwYek#opt-in", "label": "License and Collaboration Agreement (Genmab a/S)", "score": 30.4017791748, "published": true}, {"hash": "9IyrDdoXRnW", "uri": "/contracts/9IyrDdoXRnW#opt-in", "label": "License and Collaboration Agreement (Genmab a/S)", "score": 30.2484607697, "published": true}], "size": 4, "hash": "151237f285027a9d517f291ccc0d1a84", "id": 9}, {"snippet_links": [{"key": "limited-liability-company-interest", "type": "definition", "offset": [5, 39]}, {"key": "the-units", "type": "clause", "offset": [67, 76]}, {"key": "meaning-of", "type": "definition", "offset": [119, 129]}, {"key": "article-8-of-the-uniform-commercial-code", "type": "clause", "offset": [134, 174]}, {"key": "section-8", "type": "definition", "offset": [186, 195]}, {"key": "in-effect", "type": "clause", "offset": [219, 228]}, {"key": "from-time-to-time", "type": "clause", "offset": [229, 246]}, {"key": "state-of-delaware", "type": "definition", "offset": [254, 271]}, {"key": "delaware-ucc", "type": "definition", "offset": [278, 290]}, {"key": "applicable-jurisdiction", "type": "definition", "offset": [343, 366]}, {"key": "national-conference", "type": "definition", "offset": [502, 521]}, {"key": "state-laws", "type": "definition", "offset": [550, 560]}, {"key": "bar-association", "type": "definition", "offset": [587, 602]}, {"key": "on-february", "type": "clause", "offset": [603, 614]}, {"key": "other-state-ucc", "type": "definition", "offset": [635, 650]}, {"key": "purposes-of-article", "type": "clause", "offset": [662, 681]}, {"key": "any-other-state", "type": "definition", "offset": [708, 723]}, {"key": "delaware-law", "type": "clause", "offset": [729, 741]}, {"key": "local-law", "type": "clause", "offset": [763, 772]}, {"key": "the-issuer", "type": "clause", "offset": [832, 842]}, {"key": "of-units", "type": "clause", "offset": [843, 851]}], "snippet": "Each limited liability company interest in BOX Holdings (including the Units) shall constitute a \u201csecurity\u201d within the meaning of (i) Article 8 of the Uniform Commercial Code (including Section 8-102(a)(15) thereof) as in effect from time to time in the State of Delaware (the \u201cDelaware UCC\u201d) and (ii) the Uniform Commercial Code of any other applicable jurisdiction that now or thereafter substantially includes the 1994 revisions to Article 8 thereof as adopted by the American Law Institute and the National Conference of Commissioners on Uniform State Laws and approved the American Bar Association on February 14, 1995 (each, an \u201cOther State UCC\u201d). For all purposes of Article 8 of the Delaware UCC and any Other State UCC, Delaware law shall constitute the local law of BOX Holdings\u2019 jurisdiction in BOX Holdings\u2019 capacity as the issuer of Units.", "samples": [{"hash": "dNdUT4cipmA", "uri": "/contracts/dNdUT4cipmA#opt-in", "label": "Limited Liability Company Agreement", "score": 32.5655937195, "published": true}, {"hash": "agrZ75QzLmW", "uri": "/contracts/agrZ75QzLmW#opt-in", "label": "Limited Liability Company Agreement", "score": 31.3408622742, "published": true}, {"hash": "eWmv7BOCMGT", "uri": "/contracts/eWmv7BOCMGT#opt-in", "label": "Limited Liability Company Agreement", "score": 25.3504447937, "published": true}], "size": 4, "hash": "836513bb88cb96b5af3e9439ac9dfab6", "id": 8}, {"snippet_links": [{"key": "terms-and-conditions-of-this-agreement", "type": "clause", "offset": [15, 53]}, {"key": "option-to", "type": "clause", "offset": [71, 80]}, {"key": "the-development", "type": "clause", "offset": [112, 127]}, {"key": "manufacture-and-commercialization", "type": "clause", "offset": [129, 162]}, {"key": "with-respect-to", "type": "clause", "offset": [299, 314]}, {"key": "target-combination", "type": "definition", "offset": [329, 347]}, {"key": "optioned-target", "type": "definition", "offset": [357, 372]}, {"key": "to-receive", "type": "definition", "offset": [445, 455]}, {"key": "data-package", "type": "clause", "offset": [466, 478]}, {"key": "available-at", "type": "definition", "offset": [687, 699]}, {"key": "development-plan", "type": "clause", "offset": [739, 755]}, {"key": "the-contemplated", "type": "clause", "offset": [782, 798]}, {"key": "clinical-studies", "type": "clause", "offset": [799, 815]}, {"key": "phase-i-studies", "type": "clause", "offset": [903, 918]}, {"key": "budget-of", "type": "clause", "offset": [941, 950]}, {"key": "a-copy-of-the", "type": "clause", "offset": [1022, 1035]}, {"key": "directly-related-to", "type": "definition", "offset": [1140, 1159]}, {"key": "product-data", "type": "clause", "offset": [1164, 1176]}, {"key": "information-from", "type": "clause", "offset": [1185, 1201]}, {"key": "board-of-directors", "type": "definition", "offset": [1211, 1229]}, {"key": "financial-information", "type": "clause", "offset": [1231, 1252]}, {"key": "the-decision", "type": "clause", "offset": [1323, 1335]}, {"key": "in-relation-to", "type": "clause", "offset": [1365, 1379]}, {"key": "the-relevant", "type": "clause", "offset": [1380, 1392]}, {"key": "receipt-of", "type": "clause", "offset": [1453, 1463]}, {"key": "payment-of-the", "type": "clause", "offset": [1584, 1598]}, {"key": "in-fee", "type": "clause", "offset": [1603, 1609]}, {"key": "in-accordance-with", "type": "clause", "offset": [1610, 1628]}, {"key": "section-103", "type": "clause", "offset": [1629, 1641]}, {"key": "option-exercise-fee", "type": "clause", "offset": [1824, 1843]}, {"key": "section-71", "type": "definition", "offset": [1944, 1955]}, {"key": "right-to-opt", "type": "clause", "offset": [1992, 2004]}, {"key": "for-avoidance-of-doubt", "type": "clause", "offset": [2009, 2031]}, {"key": "no-obligation-to-provide", "type": "clause", "offset": [2142, 2166]}, {"key": "no-right-to", "type": "clause", "offset": [2210, 2221]}], "snippet": "Subject to the terms and conditions of this Agreement, CureVac has the option to join Genmab [*****] [*****] on the Development, Manufacture and Commercialization of any [*****] Product that is a Cocktail Product, at CureVac\u2019s sole election (\u201cOpt-In\u201d). If within [*****] of Genmab\u2019s Option Exercise with respect to such Reserved Target Combination (then an Optioned Target Combination) which might result in a Cocktail Product, CureVac requests to receive an Opt-In Data Package (as defined below), Genmab shall within [*****] of such Option Exercise supply CureVac with (i) a comprehensive preclinical data package generated under the respective Program, including all Development Data available at such time; and (ii) a high-level draft Development plan (specifying in high-level the contemplated Clinical Studies and non-clinical studies to be conducted) up until and including contemplated Clinical Phase I Studies; and (iii) a proposed budget of costs, internal and external, for the draft Development Plan, and (iv) a copy of the documentation (with any reasonably required redactions, including redactions to exclude information not directly related to the Product data such as information from Genmab\u2019s board of directors, financial information etc.) provided to Genmab\u2019s portfolio board as basis for Genmab taking the decision to undertake Option Exercise in relation to the relevant Cocktail Product (\u201cOpt-In Data Package\u201d). Within [*****] of receipt of the Opt-In Data Package, CureVac shall notify Genmab whether or not CureVac wishes to Opt-In. Upon CureVac\u2019s Opt-In and payment of the Opt-In Fee in accordance with Section 10.3 below, the Optioned Target Combination will become an \u201cOpt-In Target\u201d and any Product resulting therefrom will be an \u201cOpt-In Product\u201d. If CureVac requests an Opt-In Data Package the Option Exercise Fee under Section 10.2 shall be deferred until [*****] after CureVac has given Genmab notice under this Section 7.1, that CureVac is not exercising its right to Opt-In. For avoidance of doubt, if CureVac does not request any Opt-In Data Package within [*****] of the Option Exercise, Genmab shall have no obligation to provide such Opt-In Data Package and CureVac shall no right to Opt-In with respect to the particular Cocktail Product.", "samples": [{"hash": "gaeiYV2nMNw", "uri": "/contracts/gaeiYV2nMNw#opt-in", "label": "Collaboration and License Agreement (CureVac B.V.)", "score": 31.5790557861, "published": true}, {"hash": "3cXtnAIXdkw", "uri": "/contracts/3cXtnAIXdkw#opt-in", "label": "Collaboration and License Agreement (CureVac B.V.)", "score": 31.5598907471, "published": true}, {"hash": "bNoDBtDZX43", "uri": "/contracts/bNoDBtDZX43#opt-in", "label": "Collaboration and License Agreement (CureVac B.V.)", "score": 31.472278595, "published": true}], "size": 3, "hash": "1d5a7fae8c0ea0b1d374ff28690f48fa", "id": 10}], "next_curs": "Ck8SSWoVc35sYXdpbnNpZGVyY29udHJhY3RzcisLEhZDbGF1c2VTbmlwcGV0R3JvdXBfdjU2Ig9vcHQtaW4jMDAwMDAwMGEMogECZW4YACAA", "clause": {"title": "Opt-In", "size": 122, "children": [["effect-of-opt-in", "Effect of Opt-in"], ["opt-in-consideration", "Opt-In Consideration"], ["opt-in-for-incremental-study-in-a-non-oncology-indication", "Opt-In for Incremental Study in a Non-Oncology Indication"], ["in-for-incremental-study-in-an-oncology-indication", "In for Incremental Study in an Oncology Indication"], ["", ""]], "parents": [["members-interests", "Members Interests"], ["membership-interests-transferability", "Membership Interests Transferability"], ["general-membership-and-accounts", "General Membership and Accounts"], ["courtesy-pay-service", "Courtesy Pay Service"], ["collection-and-use-of-entrant-information", "Collection and Use of Entrant Information"]], "id": "opt-in", "related": [["combination-product", "Combination Product", "Combination Product"], ["licensed-product", "Licensed Product", "Licensed Product"], ["reformulation-of-products", "Reformulation of Products", "Reformulation of Products"], ["combination-products", "Combination Products", "Combination Products"], ["scope-of-collaboration", "Scope of Collaboration", "Scope of Collaboration"]], "related_snippets": [], "updated": "2025-11-08T04:52:06+00:00", "also_ask": ["What are the strategic advantages of including an opt-in clause versus an opt-out clause?", "Which essential elements must be drafted to ensure the opt-in is clear and enforceable?", "What are the most common legal pitfalls or ambiguities that undermine opt-in clauses?", "How do courts typically interpret and enforce opt-in provisions in contract disputes?", "How does the treatment of opt-in clauses differ across key jurisdictions or legal systems?"], "drafting_tip": "Specify the opt-in procedure and required consent format to ensure clarity and legal validity; define the effective date to prevent disputes over timing.", "explanation": "An Opt-In clause allows a party to voluntarily choose to participate in a specific provision, service, or agreement term. In practice, this clause typically requires the party to provide written notice or take a specific action to activate their participation, such as agreeing to additional services or terms beyond the base agreement. The core function of an Opt-In clause is to provide flexibility and control, ensuring that parties are not automatically bound by certain terms unless they expressly agree, thereby reducing the risk of unintended obligations."}, "json": true, "cursor": ""}}